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1. Introduction
Lung is a major site of continuous immune reactions as it encounters various foreign particles
and antigens entering the respiratory system. It is the main internal organ constantly exposed
to the external environment that contains an array of microbes and particulate matter.
Typically an adult exchanges 4.2 liters of air per minute amounting to almost 6000 liters per
day [1In fact ventilation and respiration generates an environment where both inflammatory
and anti-inflammatory response takes place continuously. However, a delicate balance is
maintained between eliciting an immune response followed by resolution and repression of
further immune reactions. Uncontrolled responses may result in injury or collateral damage
to the lung whereas a subdued immune reaction may lead to unchecked infection. Hence, an
efficient inflammatory reaction followed by precisely controlled resolution and fine-tuned
remodeling process has evolved to minimize the effects of such challenges. The immune
system of the lung is well developed to encounter this continuous challenge and disparate
demands. Both innate and adaptive immune responses contribute to the surveillance of overall
immune function in the lung. The respective immunological effector cells, T-lymphocytes,
mast cells, dendritic cells (DCs) and macrophages are present within the lung interstitium, as
early as from the pseudoglandular stage of development [2].
Macrophages are strategically distributed all over the body, present virtually in all tissues.
They represent an important part of the immune system as tissue resident cells. Macrophages
can differentiate from circulating peripheral blood mononuclear cells which migrate into tissue
in the steady state or in response to inflammation. As the most plastic cell of the hemapoetic
system, macrophages are classified depending on the milieu and specialization. Macrophages
are of various types such as alveolar (lungs), microglia (brain), kupffer cells (hepatic), splenic,
intestinal, intraocular (eyes) and bone marrow. Macrophages represent a spectrum of activated
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phenotypes rather than defined stable subpopulations. During homeostatic conditions, the
tissue resident macrophages remain in a quiescent state. Upon requirement, monocytes get
recruited and differentiated into macrophages and DCs at the site of inflammation. Mature
macrophages can further get polarized into either M1 macrophages (classical activation) or
M2 macrophages (alternative activation) and attain their respective phenotypes. They are
characterized based on their surface markers, secreted cytokines, nitric oxide enzymes,
transcription and epigenetic factors.
Macrophages serve as an effective component of innate immunity for their ability to recognize,
engulf and kill potential pathogens. Macrophages are commonly derived from monocytes and
play a crucial role in both innate and adaptive immunity [3]. They contribute to the activation
of these immune responses by synthesis and secretion of a range of pro-and anti-inflammatory
mediators thereby establishing protective immunity. Macrophages also play an important role
in the defense system as antimicrobial warriors against invading microbes such as bacteria.
Uncontrolled macrophage activity in the host is however noxious and has been linked to
various pathogenic conditions such as artherosclerosis, granulomatous disease and macro‐
phage activation syndrome [4-9]. The pivotal role of macrophages during the initiation,
regulation and termination of inflammation makes them a major target for the prevention,
control and resolution of inflammatory processes in various chronic lung diseases such as
chronic obstructive pulmonary disease (COPD) [10-13], asthma [14-16] and idiopathic
pulmonary fibrosis (IPF) [17-20].
The alveolar macrophages (AMs) are the predominant leukocyte phenotype in the lung among
all age groups (> 89%). Bronchoalveolar lavage (BAL) from healthy adults contains an average
of 91% of alveolar macrophages, 7% of lymphocytes, 1% neutrophils and 1% of mast cells [21].
In the lungs, cells of lymphoid origin are sparse when compared to cells derived from the
myeloid lineage during an acute immune response. Macrophages initiate phagocytosis and
subsequently release cytokines along with other products which orchestrate host cellular
defence. Understanding the molecular basis of macrophage polarization is an important aspect
to deal with inflammation. The microenvironment plays an important role in the phenotypic
polarization of macrophages. This polarization is driven by various factors, signals and
diseased conditions. However, the molecular basis of macrophage polarization has not been
fully explored. A major question that remains to be answered is about the function of the
different macrophage types under various conditions such as steady state, diseased and tissue-
repair. The need to understand the polarization of macrophages becomes mandatory in order
to improve the therapeutic strategies for different chronic respiratory diseases. In this chapter,
the heterogeneity of macrophages, its classification under different conditions, and the status
of its polarization in chronic respiratory diseases along with their respective functions are
discussed.
2. Monocyte heterogeneity
The mononuclear phagocyte system represents a subgroup of leukocytes described as a
population of bone marrow derived CD4+(cluster of differentiation 4) myeloid progenitor cells
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that circulate in the blood as monocytes [22]. They act as immune effector cells, equipped with
chemokine receptors and pathogen recognition receptors on its surface that mediate migration
from blood to tissues. These cells do not proliferate in a steady state condition but circulate in
blood stream, bone marrow and spleen [23, 24]. They enter the peripheral tissues during
inflammation and mature into either macrophages or inflammatory DCs which are significant
mediators of inflammatory reaction in the lung tissue. The differentiation of recruited blood
monocytes into macrophages depends on the characteristics of inflammation and is also
governed by the pulmonary microenvironment. Newly differentiated macrophages can also
activate resident macrophages or epithelial cells to secrete more inflammatory cytokines,
chemokines and other inflammatory factors which in turn result in more monocyte recruitment
to the site of inflammation.
Peripheral-blood monocytes show morphological heterogeneity, such as variability of size,
granularity and nuclear morphology [25]. In human blood, monocytes are divided into two
subsets depending upon the differential expression of cell surface markers CD14 and CD16,
commonly detected by means of cytometry. Monocytes which are CD14hi(High) and CD16–
(negative) represent the classical subset whereas monocytes with CD14hi and CD16+(positive)
expression represent the other type characterized by higher expression of major histocompat‐
ability complex class II (MHCII) and CD32 antigen [26]. The monocyte heterogeneity in mice
is differentiated with the expression of chemokine (C-C motif) receptor 2 (CCR2) and lym‐
phocyte antigen 6 complex (Ly6C). Monocytes which express CCR2, CD62, CX3CRlow
(chemokine [C-X3-C motif] receptor 1), Ly6C correspond to CD14hiCD16– (classic) human
monocytes [27]. Although monocyte heterogeneity is not completely understood, one theory
suggests that monocytes continue to develop and mature in the blood and can be recruited
into the tissues at various points during maturation continuum [28].
Plasticity is the hallmark of monocytes and it responds to various microenvironmental signals
and mount specific phenotypic functional programs. Monocytes in response to the pro-
inflammatory signals migrate to the inflamed tissue and differentiate into inflammatory
macrophages and DCs. Also in the absence of inflammation, monocytes have been thought to
enter the tissues and replenish the pool of tissue resident macrophages and DC populations
[29]. However, recent evidences suggest that tissue resident macrophages proliferate and
maintain their pool locally, independent of the circulating blood monocytes [30]. However,
the precise mechanism for this switch in the role of monocytes from one type to another is not
clear. Granulocyte macrophage-colony stimulating factor (GM-CSF) and interleukin 4 (IL4)
are able to induce the differentiation of human and mouse monocytes into DCs, irrespective
of their subsets [31, 32]. These striking similarities in the characteristic features of mouse and
human monocyte subsets establish the conserved mechanisms among the two species.
However, since most of our understanding about macrophage biology relies on in vitro studies
or severe pathological conditions of animal experimental disease models, one needs to
overcome the difficulties in establishing the in vitro and in vivo studies to have a clear
mechanistic understanding of the phenotype switching in monocytes under homeostatic
conditions. In this context, significant progress has recently been achieved in mice thereby
improving our understanding of the weak connection between circulating blood monocytes
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and resident tissue macrophages. For example it has been shown that AMs originate from fetal
monocytes, thus establishing a locally independent, self-maintained pool of highly specialized
resident tissue phagocytes. The pool is maintained by local proliferation, mainly triggered by
GM-CSF stimulation and under steady state conditions exist independent of replenishment
by blood monocytes [30, 33, 34].
3. Populations of macrophages
Macrophages can be derived from circulating monocytes and exhibit a high degree of heter‐
ogeneity like their precursors [35, 36]. However, it is still not clear whether in this way
differentiated cell will be able to functionally replace resident tissue macrophage. Heteroge‐
neity refers to the ability of macrophages to embark on different phenotypic functional
specialization depending upon the anatomical location and its microenvironment. For
example, the AMs express high pattern recognition receptors to counter the environmental
microbial challenge in the lungs. Likewise, each tissue resident macrophage has its typical
functional characterization. It is clear that macrophages represent a spectrum of activated
phenotypes rather than discrete stable subpopulation. The main function of immune surveil‐
lance remains the same for all the macrophages irrespective of its location. Macrophages play
a central role in inflammation and host defence [3] and are characterized by considerable
diversity and plasticity [37, 38].
In the lung, distinct macrophage subpopulations have been characterized primarily in
infectious disease and asthma models [39-43]. The local conditions present in the lung dictate
the differentiation and activation of monocytes and macrophages in addition to the specific
developmental pathways [25]. Two unique populations of monocytes are present in circula‐
tion. The monocytes enter lungs under steady state conditions and develop into resident tissue
interstitial macrophages and AMs [44, 45]. Inflammatory monocytes are recruited in a CCR2-
dependent manner at the time of inflammation, and develop into either an activated macro‐
phage population, known as exudative macrophages (ExMacs) or into monocyte-derived
dendritic cells (moDCs) [46]. Resident macrophages differ markedly from inflammatory
monocyte-derived macrophages in terms of morphology, phenotype, and effector functions
[42].
Resident lung interstitial macrophages and AMs express relatively lower MHCII and costi‐
mulatory molecules [47]. After activation, they produce low levels of inflammatory cytokines
and do not promote T-cell activation. In contrast, ExMacs are a major source of inflammatory
cytokines and chemokines, expressing high levels of MHCII and costimulatory molecules.
Further, they also stimulate T cell activation [46]. It is hypothesized that ExMacs are recruited
to the lung early after noninfectious lung injury and have effector functions distinct from
resident macrophages [46]. AMs in the lung provide the first line of defense against inhaled
organism and irritants [16, 44]. In addition to their phagocytic role, AMs are known to be a
critical modulator of the lung inflammatory response through the production of various pro-
inflammatory and anti-inflammatory modulators.
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4. Activation and recruitment of macrophages
The presence and evolution of distinct macrophage subsets in the lung serve specific niches in
regulating the inflammatory response and its resolution. Based on the patterns of gene
expression, protein secretion and roles in host defense mechanisms, macrophages are classified
into classically activated macrophages (CAM) and alternatively activated macrophages
(AAM). The two main macrophage subsets namely CAM (also termed as M1) and AAM
(termed as M2) have been described in analogy to T helper (Th)1 and Th2 lymphocyte
archetype activation [3]. In response to various signals, macrophages may undergo M1
classical activation [by toll like receptor (TLR) ligands and interferon gamma (IFNγ)] or M2
alternative activation [by IL4 and IL13]. M1 and M2 activation phenotypes represent two ends
of the functional spectrum of macrophage polarization [48] (Figure 1). In addition to these
stimulants, various other cytokines and interferons have also been documented in the
polarization of macrophages. Addition of transforming growth factor beta 1 (TGFβ1) to
monocytes confers the phenotype of leukocytes during in vitro condition [49], whereas
exposure to macrophage colony stimulating factors (M-CSF) induces monocytes to differen‐
tiate into macrophages under the same condition. Addition of IFNγ [or lipopolysaccharide
(LPS)] to M-CSF induces the differentiation of M1-like macrophages whereas addition of IL4
induces the differentiation of M2-like macrophages [50, 51]. A continuum of macrophage
polarization is likely to exist beyond these discrete in vitro based classifications [38].
The immune system of alveolar blood barrier in the lungs has to be tightly regulated as
pulmonary edema and inflammation can lead to thickening of alveolar walls and thereby
compromise gas exchange efficiency [52]. Alveolar macrophages play an important role in
maintaining the immune system of the lungs. Multiple subsets of monocyte derived macro‐
phages contribute to distinct stages of inflammation [23, 27]. A fully differentiated macrophage
subpopulation can change its phenotype in response to the microenvironment [48, 53, 54]. Each
signal from the microenvironment has its specific role in the process of macrophage polariza‐
tion and the macrophages change their phenotype based on the duration of exposure to the
stimulus [53-57]. Macrophages which are exposed to the environment favoring alternative
activation, switches its phenotype to M1 when it encounters activation by IFNγ or TNF [58-60].
Various molecules such as 7-oxo-cholesterol (7oxo-C), P50 have been recognized as stimulants
of polarization. 7oxo-C has a prominent impact on the phenotype of polarized M1 and M2
macrophages. It stimulates the expression of MHCII by M1 macrophages resulting in upre‐
gulation of macrophage function as antigen presenting cells (APC) that favor activation of
adaptive immune responses [61]. 7-oxoC affects human macrophage biology by skewing the
M1/M2 macrophage balance towards a pro-inflammatory profile. P50 in nuclear factor kappa
B (NF-κB) play an essential role in the orientation of macrophage polarization both in vitro
and in vivo. This regulatory subunit may play a crucial role in the control of M1 and M2 driven
inflammation [62]. Other key transcription factors for polarization are interferon regulatory
factor 5 (IRF5), signal transducer and activator of transcription 1 (STAT1) for the M1 and IRF4,
STAT6 and peroxisome proliferator activated receptor gamma (PPARγ) for the M2 pathway
[63].
Macrophage Polarization in Lung Biology and Diseases
http://dx.doi.org/10.5772/57567
33
Figure 1. Schematic representation of M1 (classical) and M2 (alternative) macrophage polarization. Several cy‐
tokines and chemokines are involved in the classical and alternative activation of macrophages. Monocytes gets differ‐
entiated into macrophages which in turn polarize to M1 type on exposure to interferon gamma (IFNγ). Various signals
define the different forms of alternative activation of macrophages. Interleukin 4 (IL4) or IL13 induces M2a subtype;
IL1β or lipopolysachharide (LPS) or immune compelxes induces M2b macrophages; and IL10 or glucocorticoids results
in M2c macrophages [38, 48, 64]. GM-CSF: granuloctye macrophage-colony stimulating factor, M-CSF: macrophage-
colony stimulating factor, MHCII: major histocompatibility complex II, iNOS: induced nitric oxide synthase, TNFα: tu‐
mour necrosis factor alpha, ARG1: arginase 1, Ym1: chitinase-like 3, Relmα: resistin like alpha, CXCL: chemokine (C-X-
C motif) ligand, CCL: chemokine (C-C motif) ligand, CCR: chemokine (C-C motif) receptor.
5. Classical activation of macrophages (CAM)
M1 macrophages are induced by IFNγ. Other factors which results in the activation of M1
macrophages are LPS, cytokines such as TNFα and GM-CSF. IL12 and IL23 are upregulated
while IL10 is down-regulated during M1 macrophage activation [65]. IL1β and TNFα act as
inducers as well as effector molecules during this process. It is also observed that Th1 response
is involved in classical macrophage activation. M1 macrophage development results in
elevated expression of the enzyme induced nitric oxide synthase (iNOS/NOS2) [66] thereby
causing production of an excess amount of nitrogen and oxygen intermediates. These cells
mediate the resistance against microbes, intracellular parasites and tumours by eliciting tissue
disruptive reactions. M1 macrophages, whose prototypical activating stimuli are IFNγ and
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LPS, exhibit potent microbicidal properties and promote strong IL12-mediated Th1 responses.
M1 macrophages express reduced levels of mannose receptor and Fc receptor for IgG (FcαR)II
[67]. Classical polarization of macrophages by cytokines affects lymphocyte proliferation. It
also determines the cytokines to be produced by activated macrophages. Pro-inflammatory
M1 macrophages release higher amounts of active matrix metalloproteinases (MMPs) such as
MMP1 and MMP9 compared to anti-inflammatory M2 cells.
6. Alternate activation of macrophages (AAM)
Macrophages activated in the presence of IL4 are known as alternatively activated macro‐
phages. IL4 along with IL13 are the major cytokines of Th2 immune responses. Macrophages
treated with IL4 and IL13 fail to present antigens to T cells and produce low levels of cytokines
in vitro [68, 69]. These macrophages are also termed as wound healing and tissue regeneration
macrophages because of their ability to produce growth factors contributing to the develop‐
ment of extracellular matrix (ECM). The main properties of M2 like macrophages are expres‐
sion of higher levels of surface scavenger, mannose and galactose type receptors that are
involved in debris clearance. It is worthy to note that although murine M1-and M2-polarized
macrophage subsets are relatively easy to distinguish based on combinatorial gene expression
profiles, the identification of equivalent subsets in humans is a more challenging task [61].
There are various forms of AAM [70]. Immune complexes along with IL10, glucocorticoids
activate M2 macrophages besides IL4 and IL13. Contrary to the M1 macrophages, during
polarization IL12 and IL23 are released at lower levels whereas scavenger, mannose and
galactose-type receptors are expressed at higher levels. IL4 was initially believed to act as anti-
inflammatory for its ability to suppress TNFα and IL6 production in macrophages. AAMs also
downregulate host protection against selected pathogens, but promote parasite encapsulation.
There are three distinct subtypes of AAMs namely M2a, M2b and M2c (Figure 1). This
classification is mainly based upon the interaction between the specific ligands and receptors
of the macrophages. The subtypes of AAMs are characterized based on the cell surface markers
and specialization. Low amounts of IL4 promote a Th2 cell response. If the stimulus persists,
it results in sufficient production of IL13, which is a dominant Th2 effector cell cytokine. IL13
in turn induces responses in both hemapoietic and non-hemapoietic cells. The diversity of
macrophage function is indicated by their polarized states, distinct subpopulations and
localization in the lung. Signals inducing M2 polarization downregulate the activities of NF-
κB and STAT1. IL4 and IL13 selectively induce CCL24, CCL17, CCL18 and CCL22 in M2a
macrophages with inhibition by IFNγ [70]. M2b macrophages express high levels of IL10 and
low levels of IL12. M2c macrophages express high levels of CXCL13, CCL16 and CCL18 [70].
Unlike other discrete leukocyte populations, macrophages maintain their plasticity and can
alter their phenotype based on the microenvironment, including the cytokine milieu among
the other factors. Importantly, M1 cells can repolarize towards M2 after the phagocytosis of
apoptotic neutrophils [71, 72] suggesting that reprogramming of inflammatory macrophage
towards M2 phenotype may be involved in the resolution phase of acute lung injury.
Macrophage Polarization in Lung Biology and Diseases
http://dx.doi.org/10.5772/57567
35
The markers of polarized macrophage were originally identified by Becker and colleagues
using membrane proteomics of macrophages [73]. AM induces high IL10 production and also
weakly express the surface receptors for M2 cells. This suggests that an early recruitment or
activation of a resident population can serve to balance the pro-inflammatory milieu. A
population of pro-inflammatory M1 cells within the interstitium is also found to be resident
cells. During the resolution phase of lung injury, this population (CD11blow and CD45hi) up
regulates the M2 markers, transferrin receptor (TFRC), chitinase –like 3 (YM1) and arginase 1
(ARG1) expression representing M1 cells in transition. A similar trend of repolarization
markers is observed among these cells located in the alveolar space. CD11bhi expressing
population of cells demonstrates higher iNOS, IL12 and ARG1 gene expression. This subpo‐
pulation coexpressing iNos and ARG1 may be regarded as representative cells which share
M1 and M2 markers [74]. The CD11bhi cells also express high amounts of IL12, another factor
by which these cells can regulate T cell responses. Cu, Zn superoxide dismutase (Cu, Zn-SOD)
polarize the macrophages to M2 phenotype, and Cu, Zn-SOD-mediated H2O2 levels modulates
M2 gene expression at the transcriptional level by redox regulation of a critical cysteine in
STAT6 [75].
7. Resident alveolar macrophages (AM)
The lung provides an appropriate example of macrophage heterogeneity within an organ and
effects of the microenvironment on the respective functions of macrophages located within
that particular environment. Based on the anatomical location within the lung, there are three
types of macrophages viz., alveolar, interstitial, and the intravascular macrophages. Each
macrophage performs specific functions, as for example, the primary function of alveolar
macrophage is the removal of particulates and microorganisms from the alveolar space. The
pulmonary intravascular macrophages perform the same function but in the circulation
whereas the interstitial macrophages might have a role in limiting inflammation, fibrosis, and
antigen presentation [76, 77]. However, the role of macrophage heterogeneity in development
of various macrophage population and its subsets is not clearly understood. As described
above, resident alveolar macrophages are derived from fetal monocytes but not blood
monocytes. However, it is still not clear whether the ExMacs are differentiated after inflam‐
mation from recruited monocytes can actually replace those developed under steady state
conditions. Further, it remains unclear whether resident macrophages in the respective tissue
niche are terminally differentiated or remain flexible to change their phenotype from one niche
to another according to the respective signals and microenvironment.
In summary AMs are an unique type of mononuclear phagocytes that populate the surface of
the lung in steady state. It forms the first line of defence against foreign particles invading the
alveolar space. AMs get activated on pathogen recognition, thereby releasing early response
cytokines such as TNFα and IL1 β. The early response also stimulate the neighboring alveolar
cells to produce chemokines. These chemokines mediate the recruitment of neutrophils,
ExMacs and lymphoctyes [78, 79]. AMs contribute to respiratory tolerance by inducing Fox3
expression in naïve T cells [80]. Noteworthy, the bone marrow with derived blood monocytes
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does not significantly contribute to the alveolar macrophage compartment during steady state
conditions. Previous alveolar macrophage half-life studies were confounded by the facts that
they did not account for the inflammatory and stimulatory effects of irradiation conditioning
regimens [79].
8. Molecular basis of macrophage polarization
Macrophage polarization is associated with significant changes at the transcriptional level,
although the two polarizing conditions are very different. M1 polarization profoundly affects
the transcriptional profile while M2 polarization results in only subtle adjustments [65]. The
investigations on the transcriptional events associated with M-CSF-dependent monocyte-to-
macrophage differentiation and subsequent M1 or M2 polarization induced by LPS and
IFNγ or IL4 demonstrated the existence of a complex network of gene regulation. Modulation
of genes involved in general cellular metabolic activities is a prominent feature of macrophage
differentiation and polarization. The enzymes such as sphingosine 1 phosphate and ceramide
1 phosphate are used to distinguish the polarized forms of macrophages as sphingosine and
ceramide kinase are selectively present in M1 and M2 macrophages respectively [65].
Classically activated macrophages include prototypic M1 polarization markers, such as the
indoleamine-pyrrole 2,3 dioxygenase, the lysosomal associated membrane protein 3, IL7R and
CCR7 [81]. Classically activated macrophages are characterized by increased expression of the
solute carrier family member SLC21A15 and SLC31A2, while alternatively activated macro‐
phages exhibit increased SLC4A7, SLC38A6 expression. In case of humans, membrane
expression of the markers CD80 and CD200R are specific for M1 and M2 polarized macro‐
phages respectively whereas mannose receptor (CD206) expression does not vary between M1
and M2. Transcript analysis further identified six markers of M1 polarization [IL-12p35,
CXCL10, CXCL11, CCL5, CCR7 and indoleamine 2,3-dioxygenase 1 (IDO1)]; five markers of
M2 polarization [TGFβ, CCL14, CCL22, scavenger receptor class B, member 1 (SCARB1)] and
several transcription factors IRF4, IRF5, STAT1, STAT6 and PPARγ] involved in macrophage
polarization. Ability of human M-CSF generated macrophage to polarize toward M1 or M2
subtype is also associated with enhanced secretion of TNFα, IL1β, IL12p40, CXCL10 and IL10
(for M1); or CCL22 (for M2). Moreover, the comparison of the expression of M1 markers in M-
CSF and GM-CSF macrophages polarized towards M1 subtype has revealed similarities [82].
Chemokine receptors are differentially expressed on polarized Th cells. Typically, CXCR3 and
CCR5 are preferentially expressed on polarized Th1 cells, whereas CCR3, CCR4 and CCR8
have been associated with the Th2 phenotypes. Distinct chemokines are associated with M1
and the various forms of M2 macrophage activation. LPS and IFNγ induce the expression of
CXCL10, CXCL9 and CCL5 [83-85]. In addition, LPS mediates induction of the CXCL10, CXCL9
and CCL5 genes through the activation of the transcription factor IRF3, which results in
IFNγ expression and subsequent STAT1 activation [85]. Further, LPS activation of monocytes
or macrophages results in the NF-κB dependent transcription of inflammatory chemokines
such as CXCL1,2,3,5,8,9 and 10; and CCL2, 3,4,5,11,17 and 22 [86]. Resistin like alpha (Relmα),
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YM1 are also expressed in higher levels and are used as phenotypic markers for M2 polarized
macrophages. CCL13, CCL14, CCL17, CCL18 and CCL24 [87] are specifically induced in M2a
macrophages [64, 88], whereas M2b macrophages rather characterized by expression of high
levels of CCL20, CXCL1, CXCL2 and CXCL3; whereas M2c macrophages express high levels
of CXCL13, CCL16 and CCL18 [64].
9. T cells and Alveolar macrophages
T cell mediated immunity is important in the lung in order to protect the host from inhaled
pathogens and environmental antigens [89-91]. Furthermore, most of the environmental
antigens encountered by the lung are innocuous. Hence it is crucial for the resident immune
cells to distinguish such inert antigens from those derived from pathogens and respond
appropriately. The immunoregulatory mechanisms employed by the lung include the
components for surfactant lining [92], products secreted by alveolar type II epithelial cells as
well as alveolar macrophages which altogether actively suppress T cell proliferation. More‐
over, AM induces anergy (immune unresponsiveness) in T cells which is reversible upon its
removal from culture [91]. T cells isolated from lungs of rodents express low levels of IL2
receptor (IL2R/CD25) [91]. The Immunoregulators associated with AM include prostaglan‐
dins, leukotrienes, IL1 and nitric oxide [89]. AMs also downregulate local pulmonary immune
responses against intratracheally administered T cell dependent antigens [93].
AMs from rat, mouse and human differ markedly in its potency to inhibit mitogen-induced T
cell proliferation. However, T cells stimulated in the presence of AMs display a similar
phenotype in all species examined, i.e. CD3 downregulation, upregulation of IL2R, increased
IL2 production and inability to respond to IL2 [94]. Thus, AMs appear to allow T cell activation
and effector functions, while selectively inhibiting T cell proliferation. The suppressive activity
of AMs is restricted to the final step in the activation process, (i.e. proliferation). Through CD3
downregulation, IL2R expression and IL2 secretion appear to proceed normally [94].
T cells from humans produce less IL2 than autologous blood-derived T cells [95]. FoxP3 is a
master regulator of regulatory T cells (Treg). FoxP3 expression is regarded as definitive marker
for cells with regulatory function in mice and humans [96, 97]. AMs obtained from BAL of
mice or humans enhance FoxP3 expression in CD4+FoxP3-T cells in vitro. Activation of naïve
T cells in the presence of either AMs or AM-conditioned media prevents T cell proliferation.
This effect can be reversed by inhibiting binding of retinoic acid to its receptor or by blocking
TGFβ1 signaling [80]. AMs induce intracellular FoxP3 expression in CD4+T cells. It promotes
IL10 while suppressing IFNγ production by the same T cell in vitro [80]. AMs induce an
immune unresponsiveness in T cells and also affects its proliferation.
10. Role of macrophages in chronic respiratory diseases
Macrophages have the ability to elicit an immune response and resolve the inflammatory
processes. The macrophages of the respiratory system are involved in the pathogenesis of
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different respiratory diseases such as COPD, asthma and pulmonary fibrosis. Different
phenotypes of macrophages are involved in these respiratory diseases which play an impor‐
tant role in either inflammation and / or resolution process.
11. Chronic obstructive pulmonary disease (COPD)
COPD is a global epidemic, mainly caused by cigarette smoke exposure (smokers disease) and
high particulate air pollution (as associated to in-house cooking) with an alarming increase in
its mortality rate [98]. COPD is characterized by an inflammatory airway obstruction and loss
of alveolar tissue thereby causing reduced respiratory surface area (emphysema). Macrophag‐
es are elevated and accumulate in small airways, bronchioles and alveoli during COPD
irrespective of the disease severity. Macrophages monitor and respond to their microenvir‐
onment that can define tissue remodelling and possibly control other inflammatory events.
AMs in the lung are an important source of both proteinases and antiproteinases. They secrete
a series MMPs (1,9 and 12) [10, 99-101] and tissue inhibitor of metalloproteinases (TIMPs). In
addition, they also secrete lysosomal cysteine proteinases [Cathepsin K, L, S (CTSK, CTSL and
CTSS respectively)] and their inhibitor cystatin C (CST3) [10, 102]. An imbalance between
proteinase and antiproteinase is considered to be an important event in the pathogenesis of
COPD [103].
Macrophage derived MMPs as well as cathepsins are elastinolytic [10, 102, 104] and are
important in airway inflammation and development of emphysema [9, 10, 101].Elastinolysis,
an essential event of emphysema [105] results in the destruction of lung tissues during COPD
[106, 107]. AMs have also been shown to release neutrophil elastase in vitro [102, 108]. There
is a positive association between macrophage numbers in the alveolar walls and the presence
of mild to moderate emphysema as well as the degree of small airways disease in patients with
COPD [109, 110]. Dysregulated expression of macrophage MMPs either directly or indirectly
by cigarette smoke exposure can lead to lung parenchyma destruction, characteristic of
emphysema.
The role of different subsets of AMs in the pathogensis of COPD is yet to be fully ascertained.
Increased expression of iNos in AMs is found in patients with COPD [111-113]. Smoke
exposure enhances the release of pro-inflammatory cytokines such as IL1β, IL6, IL8 and
TNFα [114-118] in the lungs which are markers of M1 macrophage polarization. There is also
contradictory transcriptome based evidence that M2 polarized alveolar macrophage may
contribute to COPD pathogenesis [119]. Further, COPD exacerbation, characterized by severe
shortness of breath, is a common occurrence, which is usually caused due to an infection or
exposure to environmental pollutants. Impaired phagocytosis, a characteristic feature of M1
polarized macrophages is also considered to be an important cause for increased COPD
severity [120]. Analysis of BAL fluid of COPD patients suggests that smoking cessation partly
changes the macrophage polarization from a pro-inflammatory M1 towards an anti-inflam‐
matory M2 macrophage phenotype [121]. M2 polarized alveolar macrophage have been shown
to produce MMP12 which plays an important role in cigarette smoke induced emphysema
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[122-124]. It could be considered that COPD pathogenesis is largely contributed by dysfunction
of macrophages rather than a single subset of AMs.
12. Asthma
Asthma is characterized by airway inflammation and airway hyperresponsiveness (AHR).
Macrophages also contribute significantly to the development of asthma [125]. The inflam‐
matory process of asthma is dominated by Th2 inflammation, but there is also involvement of
both types M1 and M2 macrophages [14]. The balance between different phenotypes of
macrophages changes with the severity of asthma [126]. In case of acute exacerbation of chronic
asthma, AMs are found to significantly enhance the expression of AAM markers along with
pro-inflammatory cytokines (IFNγ and TNFα) and cell surface proteins. Ironically, the cell
surface proteins associated with antigen presentation are M1 inducers [127, 128]. Elevated
serum IFNγ correlates with the severity of airway inflammation in atopic asthma, and IFNγ
has been linked to mechanisms inducing AHR [129]. It was demonstrated that IL33/ST2 plays
a significant role in the amplification of AAM polarization and chemokine production which
contribute to innate and Ag-induced airway inflammation [130].
The ability of AMs to phagocytose apoptotic cells is known as efferocytosis. Macrophage
efferocytosis is impaired in non-eosinophilic asthma to a similar degree as in COPD [131]. In
mice with less severe asthma, M1 macrophage numbers were higher and correlated negatively
with M2 macrophage counts. Lower numbers of M2-like macrophages were found in mice
exposed to house dust mites. The balance between macrophage phenotypes changes as the
severity of allergic airway inflammation increases. Influencing this imbalanced relationship
could be a novel approach to treat asthma [126]. CCL18 and YKL40 (chitinase 3-like 1) levels
and CHIT1 (chitinase 1) activity are enhanced in allergic airway inflammation and thus may
contribute to airway remodelling in asthma [132]. M2 macrophages play a role in eosinophil
and potentially other leukocyte migration patterns into asthmatic airways [133]. Dysregulation
of alveolar macrophage function results in dendritic cell-mediated mechanisms of allergic
airway inflammation [134]. AMs can also contribute to the genetic susceptibility to allergic
asthma [39].
13. Pulmonary fibrosis
Fibrosis is the result of persistent or dysregulated wound healing, usually in response to some
type of repeated injury. It is often associated with chronic inflammation, alveolar epithelial
hyperplasia and excessive deposition of ECM [135]. Lung macrophages and circulating
monocytes play an important role during pulmonary fibrosis. AMs are involved in the removal
of accumulated collagen. AAM play an important role in the development and resolution of
lung fibrosis after injury, but their growth promoting activity raise the intriguing possibility
that persistent M2 activity might contribute to the failure in resolving fibrosis in IPF patients.
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Sun and coworkers [136] reported that increased numbers of AAMs induced by over expres‐
sion of IL10 results in induction of lung fibrosis in mice. Accordingly increased expression of
CD206 (another marker of AAM) and IL4 is observed in patients with IPF and systemic
sclerosis [137, 138]. Secretion of IL4 and IL13 by T cells is required for fibroblast migration and
proliferation and their subsequent differentiation into myofibroblasts. IFNγ, in contrast,
attenuates the fibrotic response and induces collagen degradation [139]. Paired immunoglo‐
bulin like receptor beta (PIRB) contributes to the pathogenesis of pulmonary fibrosis via the
negative regulation of macrophage effector function and fibrogenic mediator expression. PIRB
negatively regulates IL4-induced macrophage activation. Various studies have also demon‐
strated the role of AAM production in pulmonary fibrosis [140]. Relmα, a hallmark M2
macrophage marker is upregulated in pulmonary fibrosis which is controlled by IL4/ IL13-and
STAT6-dependent pathways [141].
The Th2 cytokines IL4 and IL13, like TGFβ1, directly stimulate collagen synthesis in mouse
and human fibroblasts [142]. They also promote the development of the classic myofibroblast
phenotype in human lung fibroblasts [143]. Macrophages accumulate in areas of fibrotic injury
but their role remains incompletely understood. A study using silica-induced model of lung
fibrosis found that the IL4Rα-dependent differentiation of AAM is critical for the induction
and maintenance of the CD4+Th2 response required to trigger fibrosis [144]. Chitotriosidase,
an enzyme especially expressed by M2 macrophages is also overexpressed in patients with
IPF, especially in a progressing stage suggesting that this enzyme plays a role in the patho‐
genesis of diffuse lung disease-associated fibrosis [145, 146].
Polarization of macrophages to the M1 phenotype attenuates pulmonary fibrosis [65]. Fibrosis
may be independent of monocyte and lung macrophage activity during the inflammation
phase of bleomycin injury, a frequently used animal model for IPF. The depletion of lung
macrophages during the inflammatory phase of bleomycin injury has no effect on the early as
well as peak stage of lung fibrosis. However, during the progressive phase, lung macrophage
depletion reduces the degree of pulmonary fibrosis. Depletion of lung macrophages during
the resolution phase of bleomycin induced lung fibrosis slowed down the process [147].
Macrophages may promote resolution during the reversible phase of bleomycin induced
pulmonary fibrosis [148]. Overexpression of MMP9 by AMs has the capability to attenuate the
fibrosis induced by bleomycin [149]. ExMacs are recruited to the lung after noninfectious injury
by bleomycin and are the major source of macrophages derived CXCL10 [46]. ExMacs are
CD11c+, MHCIIin Gr-1 int and are separated from resident AMs by high expression of both
CD11b and CX3CR1. Everson and colleagues [147] separated AMs into 18 density defined
subpopulations. Bleomycin altered the proportions of these subpopulations and enhanced the
production of TNFα production in these specific subpopulations. Bleomycin-treated Pirb(-/-)
mice displayed an increased expression of collagen and IL4 associated profibrogenic markers
Relmα, MMP12, TIMP1, and osteopontin, which were localized to AMs. Thus, macrophages
may have a role in resolution during the reversible phase of bleomycin induced pulmonary
fibrosis [148].
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14. Environmental exposure to particle inhalation
Epidemiologic and occupational studies show that exposure to high concentrations of ambient
particulate matter cause cardiopulmonary health effects, including exacerbation of pre-
existing lung disease as well as the development of respiratory infections. Particle related
oxidative stress and inflammatory responses are considered to be key for the subsequent health
effects, but the precise mechanism how inhaled poorly soluble, sterile, endotoxin free particle
induce pulmonary inflammation is not well understood [150]. Since the size of the inhaled
material determines their penetration depth into the lungs, smaller particle (<100nm) cause
higher alveolar lung burden than bigger sized particles. Lung surface macrophages (i.e. AMs)
do not efficiently phagocytose small, sub-100nm sized, so called ultrafine particles (UFP) or
nanoparticles (NP), but take them up in a rather sporadic and unspecific way [151]. But the
evidence that UFP bypass the most important clearance mechanism for particles deposited in
the alveoli, namely phagocytic uptake by macrophages, requires further clarification as to
whether these results are specific for the material, the size or other characteristics of the
particles. A rethinking of clearance pathways for inhaled UFP is therefore considered neces‐
sary [151].
Inhalation of ultrafine carbon particles triggers a biphasic pro-inflammatory process in the
lung, involving the activation of macrophages and the upregulation of immunomodulatory
proteins [152]. Higher doses cause a distinct inflammatory response characterized by the
release of pro-inflammatory cytokines and accumulation of inflammatory leukocytes [153]. A
single exposure to these carbon particles however causes only a transient inflammatory
response, which resolves within one week after treatment [154]. Black carbon laden AMs
however are observed even at much later time points when no inflammatory stimulation in
the lungs is detectable. Whether the immunological activity of these long-living tissue
macrophages gets changed remains unknown. In animal experiments, when lung inflamma‐
tion for example is induced by titanium di oxide (TiO2) particles in rats, AMs induce the
production of IL-13 and IL-25 production. This in turn modulates the inflammatory response
[155]. When exposed to gold NPs, it is found that AMs efficiently internalize NPs by endocy‐
tosis, and rearrangements of vesicles and of NPs within the vesicles of macrophages occurred
[156]. The uptake of gold particles by AMs is limited, though to a low degree, systemic particle
translocation is reported. To summarise, inhaled NPs or UFPs pose high burden to the integrity
of lungs as these particles penetrate into the susceptible alveolar region due to the ineffective
clearance mechanisms. Whether an activation of lung macrophages, potentially caused by
particle-cell interactions, results in a change of their immunological properties thereby
increasing the susceptibility for secondary infection warrants further investigations.
15. Conclusion
Macrophages are essential to host defense mechanism. The alveolar macrophages exhibit
unique properties, including uncharacteristic phenotypic features, remarkable plasticity and
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functionality. Various factors of the lung microenvironment define the polarization of
macrophages. The temporal changes in the polarization of macrophages during chronic
pulmonary diseases help in the regulation of tissue repair and remodeling. Thus understand‐
ing of the molecular mechanisms and microenvironment biology of macrophage polarization
is a crucial step in evolving novel therapeutic strategies for treating chronic respiratory
diseases.
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